Clinical Trial Update: A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase II trial evaluates the efficacy of combining erlotinib (Tarceva) with silybin-phytosome (Siliphos) in patients with EGFR-mutant non-small cell lung canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Siliphos
• Tarceva (erlotinib)

Snippet

Sponsor: MedicalLogic | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: UNKNOWN